** Medadvisor MDR.AX slides 12.7% to A$0.096, lowest since March 21
** Medication solutions co expects FY25 loss before interest, taxes, depreciation and amortization to be in the A$2.6 mln ($1.6 mln)-A$5.5 mln range
** Co reported FY24 EBITDA at A$7 mln
** MDR expects FY25 revenue between A$93 mln and A$99 mln, lower than year-ago A$122 mln
** Stock on track for weakest session since March 21
** MDR sheds 51.1% YTD
($1 = A$1.6023)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.